Skip to main content
Log in

Pharmacologic properties of (−)-3PPP (preclamol) in man

  • Full Papers
  • Published:
Journal of Neural Transmission / General Section JNT Aims and scope Submit manuscript

Summary

The dopamine (DA) autoreceptor agonist (−)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar “rising dose” placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200–500 pmoles/ml after the intramuscular drug doses of 30–40 mg. Drug half life is 2–2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (−)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andreasen N (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788

    Google Scholar 

  • Arnt J, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur J Pharmacol 86: 185–198

    Google Scholar 

  • Baldessarini RJ (1991) S(+)Aporphines as potential limbic-selective antipsychotic agents. Presented at the International Congress on Schizophrenia Research, Tucson, Arizona

  • Bergstrom DA, Carlson JH, Bromley SD, Jackson DM, Walters JR (1986) Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors. Eur J Pharmacol 13: 124(1–2): 75–84

    Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–145

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985a) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985b) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62: 171–207

    Google Scholar 

  • Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648

    Google Scholar 

  • Corsini GU, Pitzalis GF, Bernardi F, Bocchetta A, Del Zompo M (1981) The use of dopamine agonists in the treatments of schizophrenia. Neuropharmacology 20: 1309–1313

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483

    Google Scholar 

  • Ferrier EC, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br J Psychiatry 144: 341–348

    Google Scholar 

  • Frohman LA, Stachura ME (1975) Neuropharmacologic control of neuroendocrine function in man. Metabolism 24: 211–234

    Google Scholar 

  • Hjorth S, Carlsson A, Clark D, Svensson K, Wikström H, Sanchez D, Lindberg P, Hacksell U, Arvidsson L-E, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81: 89–99

    Google Scholar 

  • Klein DF, Davis JM (1969) Review of antipsychotic drug literature. Diagnosis and drug treatment of psychiatric disorders. Williams and Wilkins, Baltimore, pp 61–63

    Google Scholar 

  • Levy MI, Davis BM, Mohs RC, Kendler KS, Mathe AA, Trigos G, Horvath TB, Davis KL (1984) Apomorphine and schizophrenia: treatment, CSF, and neuroendocrine responses. Arch Gen Psychiatry 41: 520–524

    Google Scholar 

  • Magnusson T, Carlsson A, Lindberg P, Sanchez D (1983) Evidence for activation of dopaminergic autoreceptors by (−)-3-PPP. Acta Pharmaceut Suec 1: 16–18

    Google Scholar 

  • Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Reports 10: 799–812

    Google Scholar 

  • Svensson L, Ahlenius S (1983) Suppression of exploratory locomotor activity in the rat by the local application of (−)3-PPP into the nucleus accumbens. Eur J Pharmacol 88: 393–397

    Google Scholar 

  • Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568

    Google Scholar 

  • Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL (1986) Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 43: 398–402

    Google Scholar 

  • Walinder J, Skott A, Carlsson A, Roos BE (1976) Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. Arch Gen Psychiatry 33: 501–505

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamminga, C.A., Cascella, N.G., Lahti, R.A. et al. Pharmacologic properties of (−)-3PPP (preclamol) in man. J. Neural Transmission 88, 165–175 (1992). https://doi.org/10.1007/BF01244730

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01244730

Keywords

Navigation